Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of luxdegalutamide (JSB462) plus abiraterone in adults with metastatic hormone-sensitive prostate cancer
CTR20253928Phase 2Active
- Sponsor
- Novartis
- Start
- Jan 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of luxdegalutamide in prostate cancer (PCa), sponsored by Novartis. Started Jan 2026; status: active.
02
Drugs
luxdegalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20253928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253928.